- ►jcojournal.org A O'Donnell, S Faivre, HA Burris III, D Rea, … - Journal of Clinical Oncology, 2008 - jcojournal.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Purpose To identify the optimal regimen and dosage of the oral mammalian ... Cited by 51 - Related articles - All 6 versions
CM Hartford, MJ Ratain - Clinical Pharmacology & Therapeutics, 2007 - nature.com The molecular target of rapamycin (mTOR) is central to a complex intracellular
signaling pathway and is involved in diverse processes including cell growth and
proliferation, angiogenesis, autophagy, and metabolism. Although sirolimus ( ... Cited by 28 - Related articles - All 3 versions
I Buhaescu, H Izzedine, A Covic - Therapeutic drug monitoring, 2006 - journals.lww.com Abstract: Sirolimus is a potent immunosuppressant drug with a novel mechanism of
action. It inhibits the mammalian target of rapamycin (mTOR) and blocks the cell
cycle of various cell types, including T- and B-lymphocytes. Sirolimus is ... Cited by 22 - Related articles - BL Direct - All 6 versions
- ►oxfordjournals.org SM Weiner, L Sellin, O Vonend, P Schenker, … - Nephrology Dialysis Transplantation, 2007 - ERA-EDTA Results. Eleven out of 80 patients (14%) with late switch to sirolimus developed
pneumonitis, in contrast to none of the 35 patients with de novo use of
sirolimus. The mean sirolimus trough level at presentation was 16.7 µg/l ... Cited by 20 - Related articles - BL Direct - All 3 versions
J Pascual - Nephrology Dialysis Transplantation, 2006 - ERA-EDTA Abstract Everolimus is a proliferation signal inhibitor (PSI)/ mammalian target
of rapamycin inhibitor that is structurally similar to sirolimus, but with a
number of important pharmacokinetic differences, including a shorter ... Cited by 18 - Related articles - BL Direct - All 6 versions
RJ Roberts, AC Wells, E Unitt, M Griffiths, … - Hepatology - interscience.wiley.com Sirolimus-induced pneumonitis has emerged as a potentially serious complication
in renal transplantation but only single case reports of this condition have
been described after liver transplantation (LT), where experience with ... Cited by 12 - Related articles - BL Direct - All 4 versions
RJ Amato, J Jac, S Giessinger, S Saxena, JP … - Cancer, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 12 - Related articles - All 2 versions
P De Simone, S Petruccelli, A Precisi, P Carrai … - Transplantation Proceedings, 2007 - Elsevier Everolimus (EVER) and sirolimus (SIR) belong to a novel class of
immunosuppressants—the proliferation signal inhibitors–whose
antiproliferative, antifibrotic properties and lack of renal and ... Cited by 9 - Related articles - All 11 versions
RW Shepherd, Y Turmelle, M Nadler, JA … - American Journal of Transplantation, 2008 - interscience.wiley.com Rejection and infection are important adverse events after pediatric liver
transplantation, not previously subject to concurrent risk analysis. Of 2291
children (<18 years), rejection occurred at least once in 46%, serious ... Cited by 9 - Related articles - BL Direct - All 4 versions
V Expósito, JA Vázquez de Prada, JJ Gómez- … - Journal of Heart and Lung Transplantation, 2008 - Elsevier Pulmonary toxicity (PT) is emerging as a frequent and serious complication of
sirolimus, a proliferation signal inhibitor (PSI) used in solid-organ
transplantation. Everolimus is a more recently developed PSI with molecular ... Cited by 5 - Related articles - All 18 versions
